Search

Your search keyword '"Foerster, Beat"' showing total 260 results
Start Over Author "Foerster, Beat"
260 results on '"Foerster, Beat"'

3. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study

Author

Marcq, Gautier, Foerster, Beat, Abufaraj, Mohammad, Matin, Surena F., Azizi, Mounsif, Gupta, Mohit, Li, Wei-Ming, Seisen, Thomas, Clinton, Timothy, Xylinas, Evanguelos, Mir, M. Carmen, Schweitzer, Donald, Mari, Andrea, Kimura, Shoji, Bandini, Marco, Mathieu, Romain, Ku, Ja H., Guruli, Georgi, Grabbert, Markus, Czech, Anna K., Muilwijk, Tim, Pycha, Armin, D’Andrea, David, Petros, Firas G., Spiess, Philippe E., Bivalacqua, Trinity, Wu, Wen-Jeng, Rouprêt, Morgan, Krabbe, Laura-Maria, Hendricksen, Kees, Egawa, Shin, Briganti, Alberto, Moschini, Marco, Graffeille, Vivien, Autorino, Riccardo, John, Patricia, Heidenreich, Axel, Chlosta, Piotr, Joniau, Steven, Soria, Francesco, Pierorazio, Phillip M., Shariat, Shahrokh F., and Kassouf, Wassim

Published
2022
Full Text
View/download PDF

5. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study

Author

Soria, Francesco, Moschini, Marco, D’andrea, David, Abufaraj, Mohammad, Foerster, Beat, Mathiéu, Romain, Gust, Killian M., Gontero, Paolo, Simone, Giuseppe, Meraney, Anoop, Krishna, Suprita, Konety, Badrinath, Rouprêt, Morgan, Perry, Matthew, Rowe, Edward, Ploussard, Guillaume, Boorjian, Stephen A., Wiklund, Peter, Sooriakumaran, Prasanna, and Shariat, Shahrokh F.

Published
2020
Full Text
View/download PDF

6. Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma

Author

Voskuilen, Charlotte S., Schweitzer, Donald, Jensen, Jørgen Bjerggaard, Nielsen, Anna M., Joniau, Steven, Muilwijk, Tim, Necchi, Andrea, Azizi, Mounsif, Spiess, Philippe E., Briganti, Alberto, Bandini, Marco, Goffin, Karolien, Bouchelouche, Kirsten, van Werkhoven, Erik, Shariat, Shahrokh F., Xylinas, Evanguelos, Azawi, Nessn H., Ku, Ja Hyeon, Foerster, Beat, van Rhijn, Bas W.G., Vegt, Erik, and Hendricksen, Kees

Published
2020
Full Text
View/download PDF

18. Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma

Author

Rieken, Malte, Boorjian, Stephen A., Kluth, Luis A., Capitanio, Umberto, Briganti, Alberto, Thompson, R. Houston, Leibovich, Bradley C., Krabbe, Laura-Maria, Margulis, Vitaly, Raman, Jay D., Regelman, Mikhail, Karakiewicz, Pierre I., Rouprêt, Morgan, Abufaraj, Mohammad, Foerster, Beat, Gönen, Mithat, and Shariat, Shahrokh F.

Published
2019
Full Text
View/download PDF

28. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy

Author

Moschini, Marco, Foerster, Beat, Abufaraj, Mohammad, Soria, Francesco, Seisen, Thomas, Roupret, Morgan, Colin, Pierre, De la Taille, Alexandre, Peyronnet, Benoit, Bensalah, Karim, Herout, Roman, Wirth, Manfred Peter, Novotny, Vladimir, Chlosta, Piotr, Bandini, Marco, Montorsi, Francesco, Simone, Giuseppe, Gallucci, Michele, Romeo, Giuseppe, Matsumoto, Kazumasa, Karakiewicz, Pierre, Briganti, Alberto, and Shariat, Shahrokh F.

Published
2017
Full Text
View/download PDF

31. Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy

Author

Rieken, Malte, Shariat, Shahrokh F., Karam, Jose A., Foerster, Beat, Khani, Francesca, Gust, Kilian, Abufaraj, Mohammad, Wood, Christopher G., Weizer, Alon Z., Raman, Jay D., Guo, Charles C., Rioux-Leclercq, Nathalie, Haitel, Andrea, Bensalah, Karim, Lotan, Yair, Bachmann, Alexander, De Marzo, Angelo M., Robinson, Brian D., and Margulis, Vitaly

Published
2017
Full Text
View/download PDF

32. Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original investigations volume 35, issue 6, June 2017, pages 356-362

Author

Soria, Francesco, primary, Lucca, Ilaria, additional, Moschini, Marco, additional, Mathieu, Romain, additional, Rouprêt, Morgan, additional, Karakiewicz, Pierre I, additional, Briganti, Alberto, additional, Rink, Michael, additional, Gust, Kilian M, additional, Hassler, Melanie R, additional, Foerster, Beat, additional, Abufarraj, Mohammad, additional, Haitel, Andrea, additional, Klatte, Tobias, additional, and Shariat, Shahrokh F, additional

Published
2022
Full Text
View/download PDF

34. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study

Author

Foerster, Beat, primary, Abufaraj, Mohammad, additional, Matin, Surena F., additional, Azizi, Mounsif, additional, Gupta, Mohit, additional, Li, Wei-Ming, additional, Seisen, Thomas, additional, Clinton, Timothy, additional, Xylinas, Evanguelos, additional, Mir, M. Carmen, additional, Schweitzer, Donald, additional, Mari, Andrea, additional, Kimura, Shoji, additional, Bandini, Marco, additional, Mathieu, Romain, additional, Ku, Ja H., additional, Marcq, Gautier, additional, Guruli, Georgi, additional, Grabbert, Markus, additional, Czech, Anna K., additional, Muilwijk, Tim, additional, Pycha, Armin, additional, D’Andrea, David, additional, Petros, Firas G., additional, Spiess, Philippe E., additional, Bivalacqua, Trinity, additional, Wu, Wen-Jeng, additional, Rouprêt, Morgan, additional, Krabbe, Laura-Maria, additional, Hendricksen, Kees, additional, Egawa, Shin, additional, Briganti, Alberto, additional, Moschini, Marco, additional, Graffeille, Vivien, additional, Kassouf, Wassim, additional, Autorino, Riccardo, additional, Heidenreich, Axel, additional, Chlosta, Piotr, additional, Joniau, Steven, additional, Soria, Francesco, additional, Pierorazio, Phillip M., additional, and Shariat, Shahrokh F., additional

Published
2021
Full Text
View/download PDF

35. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study

Author

Foerster, Beat, Abufaraj, Mohammad, Matin, Surena F., Azizi, Mounsif, Gupta, Mohit, Li, Wei-Ming, Seisen, Thomas, Clinton, Timothy, Xylinas, Evanguelos, Mir, M. Carmen, Schweitzer, Donald, Mari, Andrea, Kimura, Shoji, Bandini, Marco, Mathieu, Romain, Ku, Ja H., Marcq, Gautier, Guruli, Georgi, Grabbert, Markus, Czech, Anna K., Muilwijk, Tim, Pycha, Armin, D'Andrea, David, Petros, Firas G., Spiess, Philippe E., Bivalacqua, Trinity, Wu, Wen-Jeng, Roupret, Morgan, Krabbe, Laura-Maria, Hendricksen, Kees, Egawa, Shin, Briganti, Alberto, Moschini, Marco, Graffeille, Vivien, Kassouf, Wassim, Autorino, Riccardo, Heidenreich, Axel, Chlosta, Piotr, Joniau, Steven, Soria, Francesco, Pierorazio, Phillip M., Shariat, Shahrokh F., Foerster, Beat, Abufaraj, Mohammad, Matin, Surena F., Azizi, Mounsif, Gupta, Mohit, Li, Wei-Ming, Seisen, Thomas, Clinton, Timothy, Xylinas, Evanguelos, Mir, M. Carmen, Schweitzer, Donald, Mari, Andrea, Kimura, Shoji, Bandini, Marco, Mathieu, Romain, Ku, Ja H., Marcq, Gautier, Guruli, Georgi, Grabbert, Markus, Czech, Anna K., Muilwijk, Tim, Pycha, Armin, D'Andrea, David, Petros, Firas G., Spiess, Philippe E., Bivalacqua, Trinity, Wu, Wen-Jeng, Roupret, Morgan, Krabbe, Laura-Maria, Hendricksen, Kees, Egawa, Shin, Briganti, Alberto, Moschini, Marco, Graffeille, Vivien, Kassouf, Wassim, Autorino, Riccardo, Heidenreich, Axel, Chlosta, Piotr, Joniau, Steven, Soria, Francesco, Pierorazio, Phillip M., and Shariat, Shahrokh F.

Abstract

Background: Several groups have proposed features to identify low-risk patients who may benefit from endoscopic kidney-sparing surgery in upper tract urothelial carcinoma (UTUC). Objective: To evaluate standard risk stratification features, develop an optimal model to identify >= pT2/N+ stage at radical nephroureterectomy (RNU), and compare it with the existing unvalidated models. Design, setting, and participants: This was a collaborative retrospective study that included 1214 patients who underwent ureterorenoscopy with biopsy followed by RNU for nonmetastatic UTUC between 2000 and 2017. Outcome measurements and statistical analysis: We performed multiple imputation of chained equations for missing data and multivariable logistic regression analysis with a stepwise selection algorithm to create the optimal predictive model. The area under the curve and a decision curve analysis were used to compare the models. Results and limitations: Overall, 659 (54.3%) and 555 (45.7%) patients had <= pT1N0/Nx and >= pT2/N+ disease, respectively. In the multivariable logistic regression analysis of our model, age (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.0-1.03, p = 0.013), high-grade biopsy (OR 1.81, 95% CI 1.37-2.40, p < 0.001), biopsy cT1+ staging (OR 3.23, 95% CI 1.93-5.41, p < 0.001), preoperative hydronephrosis (OR 1.37 95% CI 1.04-1.80, p = 0.024), tumor size (OR 1.09, 95% CI 1.01-1.17, p = 0.029), invasion on imaging (OR 5.10, 95% CI 3.32-7.81, p < 0.001), and sessile architecture (OR 2.31, 95% CI 1.58-3.36, p < 0.001) were significantly associated with >= pT2/pN+ disease. Compared with the existing models, our model had the highest performance accuracy (75% vs 66-71%) and an additional clinical net reduction (four per 100 patients). Conclusions: Our proposed risk-stratification model predicts the risk of harboring >= pT2/N+ UTUC with reliable accuracy and a clinical net benefit outperforming the current risk-stratification models. Patient summary: We develop

Published
2021

36. Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer

Author

D’Andrea, David, Foerster, Beat, Matin, Surena F., Ku, Ja H., Muilwijk, Tim, Monteiro, Leonardo L., Liao, Ross, Petros, Firas G., Spiess, Philippe E., Bivalacqua, Trinity J., Hendricksen, Kees, van Rhijn, Bas W.G., Shabsigh, Ahmad, Briganti, Alberto, Joniau, Steven, Kassouf, Wassim, Pierorazio, Phillip M., Margulis, Vitaly, Necchi, Andrea, and Shariat, Shahrokh F.

Published
2020
Full Text
View/download PDF

38. Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma

Author

Foerster, Beat, primary, Abufaraj, Mohammad, additional, Petros, Firas, additional, Azizi, Mounsif, additional, Gupta, Mohit, additional, Schweitzer, Donald, additional, Margulis, Vitaly, additional, Iwata, Takehiro, additional, Kimura, Shoji, additional, Shabsigh, Ahmad, additional, Briganti, Alberto, additional, Ku, Ja H., additional, Muilwijk, Tim, additional, Kassouf, Wassim, additional, Matin, Surena F., additional, Spiess, Philippe E., additional, Pierorazio, Phillip M., additional, Hendricksen, Kees, additional, Shariat, Shahrokh F., additional, Clinton, Timothy, additional, Broutian, Tatevik, additional, Bandini, Marco, additional, Monteiro, Leonardo L., additional, Liao, Ross, additional, Moschini, Marco, additional, Bivalacqua, Trinity J., additional, Krabbe, Laura-Maria, additional, Nasu, Yasutomo, additional, Egawa, Shin, additional, Joniau, Steven, additional, John, Hubert, additional, van der Heijden, Michiel S., additional, Glybochko, Petr V., additional, Fajkovic, Harun, additional, Singla, Nirmish, additional, and Necchi, Andrea, additional

Published
2020
Full Text
View/download PDF

40. MP82-06 NEW CLASSIFICATION FOR UPPER TRACT UROTHELIAL CARCINOMA TO ENHANCE RISK STRATIFICATION OF PATIENTS ELIGIBLE TO ENDOSCOPIC MANAGEMENT: AN INTERNATIONAL COLLABORATIVE STUDY

Author

Marcq*, Gautier, primary, Foerster, Beat, additional, Matin, Surena F., additional, Azizi, Mounsif, additional, Gupta, Mohit, additional, Li, Wei-Ming, additional, Seisen, Thomas, additional, Clinton, Timothy, additional, Xylinas, Evanguelos, additional, Carmen, Mir, additional, Rubio-Briones, Jose, additional, Schweitzer, Donald, additional, Mari, Andrea, additional, Kimura, Shoji, additional, Bandini, Marco, additional, Mathieu, Romain, additional, Ku, Ja H., additional, Anele, Uzoma, additional, Grabbert, Markus, additional, Czech, Anna K., additional, Muilwijk, Tim, additional, Pycha, Armin, additional, Abufaraj, Mohammad, additional, D’Andrea, David, additional, Petros, Firas, additional, Spiess, Philippe E., additional, Bivalacqua, Trinity, additional, Wu, Wen-Jengz, additional, Rouprêt, Morgan, additional, Krabbe, Laura-Maria, additional, Hendricksen, Kees, additional, Egawa, Shin, additional, Briganti, Alberto, additional, Moschini, Marco, additional, Autorino, Riccardo, additional, Heidenreich, Axel, additional, Chlosta, Piotr, additional, Joniau, Steven, additional, Soria, Francesco, additional, Pierorazio, Phillip, additional, Shariat, Shahrokh F., additional, and Kassouf, Wassim, additional

Published
2020
Full Text
View/download PDF

43. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma.

Author

Pradere, Benjamin, D'Andrea, David, Schuettfort, Victor M., Foerster, Beat, Quhal, Fahad, Mori, Keiichiro, Abufaraj, Mohammad, Margulis, Vitaly, Deuker, Marine, Briganti, Alberto, Muilwijk, Tim, Hendricksen, Kees, Lotan, Yair, Karakiewic, Pierre, and F.Shariat, Shahrokh

Subjects
NEOADJUVANT chemotherapy, TRANSITIONAL cell carcinoma, LOGISTIC regression analysis, TREATMENT effectiveness, REGRESSION analysis, BLADDER cancer
Abstract

Purpose: The accurate selection of patients who are most likely to benefit from neoadjuvant chemotherapy is an important challenge in oncology. Serum AGR has been found to be associated with oncological outcomes in various malignancies. We assessed the association of pre-therapy serum albumin-to-globulin ratio (AGR) with pathologic response and oncological outcomes in patients treated with neoadjuvant platin-based chemotherapy followed by radical nephroureterectomy (RNU) for clinically non-metastatic UTUC. Methods: We retrospectively included all clinically non-metastatic patients from a multicentric database who had neoadjuvant platin-based chemotherapy and RNU for UTUC. After assessing the pretreatment AGR cut‐off value, we found 1.42 to have the maximum Youden index value. The overall population was therefore divided into two AGR groups using this cut‐off (low, < 1.42 vs high, ≥ 1.42). A logistic regression was performed to measure the association with pathologic response after NAC. Univariable and multivariable Cox regression analyses tested the association of AGR with OS and RFS. Results: Of 172 patients, 58 (34%) patients had an AGR < 1.42. Median follow-up was 26 (IQR 11–56) months. In logistic regression, low AGR was not associated with pathologic response. On univariable analyses, pre-therapy serum AGR was neither associated with OS HR 1.15 (95% CI 0.77–1.74; p = 0.47) nor RFS HR 1.48 (95% CI 0.98–1.22; p = 0.06). These results remained true regardless of the response to NAC. Conclusion: Pre-therapy low serum AGR before NAC followed by RNU for clinically high-risk UTUC was not associated with pathological response or long-term oncological outcomes. Biomarkers that can complement clinical factors in UTUC are needed as clinical staging and risk stratification are still suboptimal leading to both over and under treatment despite the availability of effective therapies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. The impact of moderate wine consumption on the risk of developing prostate cancer

Author

Vartolomei,Mihai, Kimura,Shoji, Ferro,Matteo, Foerster,Beat, Abufaraj,Mohammad, Briganti,Alberto, Karakiewicz,Pierre, and Shariat,Shahrokh

Subjects
Clinical Epidemiology
Abstract

Mihai Dorin Vartolomei,1,2,* Shoji Kimura,2,3,* Matteo Ferro,4 Beat Foerster,2,5 MohammadAbufaraj,2,6 Alberto Briganti,7 Pierre I Karakiewicz,8 Shahrokh F Shariat2,9,10,11 1Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania; 2Department of Urology, Medical University of Vienna, Vienna, Austria; 3Department of Urology, Jikei University School of Medicine, Tokyo, Japan; 4Division of Urology, European Institute of Oncology, Milan, Italy; 5Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland; 6Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; 7Department of Urology, Vita Salute San Raffaele University, Milan, Italy; 8Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada; 9Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; 10 Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; 11Department of Urology, Weill Cornell Medical College, New York, NY, USA *These authors contributed equally to this work Objective: To investigate the impact of moderate wine consumption on the risk of prostate cancer (PCa). We focused on the differential effect of moderate consumption of red versus white wine.Design: This study was a meta-analysis that includes data from case–control and cohort studies.Materials and methods: A systematic search of Web of Science, Medline/PubMed, and Cochrane library was performed on December 1, 2017. Studies were deemed eligible if they assessed the risk of PCa due to red, white, or any wine using multivariable logistic regression analysis. We performed a formal meta-analysis for the risk of PCa according to moderate wine and wine type consumption (white or red). Heterogeneity between studies was assessed using Cochrane’s Q test and I2 statistics. Publication bias was assessed using Egger’s regression test.Results: A total of 930 abstracts and titles were initially identified. After removal of duplicates, reviews, and conference abstracts, 83 full-text original articles were screened. Seventeen studies (611,169 subjects) were included for final evaluation and fulfilled the inclusion criteria. In the case of moderate wine consumption: the pooled risk ratio (RR) for the risk of PCa was 0.98 (95% CI 0.92–1.05, p=0.57) in the multivariable analysis. Moderate white wine consumption increased the risk of PCa with a pooled RR of 1.26 (95% CI 1.10–1.43, p=0.001) in the multivariable analysis. Meanwhile, moderate red wine consumption had a protective role reducing the risk by 12% (RR 0.88, 95% CI 0.78–0.999, p=0.047) in the multivariable analysis that comprised 222,447 subjects.Conclusions: In this meta-analysis, moderate wine consumption did not impact the risk of PCa. Interestingly, regarding the type of wine, moderate consumption of white wine increased the risk of PCa, whereas moderate consumption of red wine had a protective effect. Further analyses are needed to assess the differential molecular effect of white and red wine conferring their impact on PCa risk. Keywords: wine, prostate cancer, alcohol, risk of cancer, meta-analysis

Published
2018

45. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer

Author

Kimura, Shoji, primary, D’Andrea, David, additional, Iwata, Takehiro, additional, Foerster, Beat, additional, Janisch, Florian, additional, Parizi, Mehdi Kardoust, additional, Moschini, Marco, additional, Briganti, Alberto, additional, Babjuk, Marko, additional, Chlosta, Piotr, additional, Karakiewicz, Pierre I., additional, Enikeev, Dmitry, additional, Rapoport, Leonid M., additional, Seebacher, Veronica, additional, Egawa, Shin, additional, Abufaraj, Mohammad, additional, and Shariat, Shahrokh F., additional

Published
2019
Full Text
View/download PDF

47. Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis

Author

Kimura, Shoji, primary, Abufaraj, Mohammad, additional, Janisch, Florian, additional, Iwata, Takehiro, additional, Parizi, Mehdi Kardoust, additional, Foerster, Beat, additional, Fossati, Nicola, additional, Briganti, Alberto, additional, Egawa, Shin, additional, Hartenbach, Markus, additional, and Shariat, Shahrokh F., additional

Published
2019
Full Text
View/download PDF

50. Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes

Author

Abufaraj, Mohammad, primary, Foerster, Beat, additional, Schernhammer, Eva, additional, Moschini, Marco, additional, Kimura, Shoji, additional, Hassler, Melanie R., additional, Preston, Mark A., additional, Karakiewicz, Pierre I., additional, Remzi, Mesut, additional, and Shariat, Shahrokh F., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results